{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:44:55Z","timestamp":1762980295957,"version":"build-2065373602"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"vor","delay-in-days":956,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.repc.2016.04.006","type":"journal-article","created":{"date-parts":[[2016,8,6]],"date-time":"2016-08-06T05:39:02Z","timestamp":1470461942000},"page":"485-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Organiza\u00e7\u00e3o e implementa\u00e7\u00e3o de uma consulta de cardio\u2010oncologia"],"prefix":"10.1016","volume":"35","author":[{"given":"Manuela","family":"Fiuza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonor","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreia","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Rita","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Nobre Menezes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00edlia","family":"Jorge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto Jos\u00e9","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2016.04.006_bib0305","unstructured":"Causas de morte 2013 [acessado 22 Nov 2015]. Edi\u00e7\u00e3o 2015. Editor: Instituto Nacional de Estat\u00edstica, I.P. www.ine.pt."},{"key":"10.1016\/j.repc.2016.04.006_bib0310","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.repc.2016.04.006_bib0315","first-page":"220","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin."},{"issue":"53","key":"10.1016\/j.repc.2016.04.006_bib0320","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"16","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2016.04.006_bib0325","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pcad.2010.05.006","article-title":"Cardiac toxicity from systemic cancer therapy: a comprehensive review","volume":"53","author":"Curigliano","year":"2010","journal-title":"Prog Cardiovasc Dis."},{"key":"10.1016\/j.repc.2016.04.006_bib0330","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab\u2010related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.repc.2016.04.006_bib0335","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy\u2010related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.repc.2016.04.006_bib0340","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet."},{"key":"10.1016\/j.repc.2016.04.006_bib0345","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1345\/aph.1L426","article-title":"Intricacies of bevacizumab\u2010induced toxicities and their management","volume":"43","author":"Gressett","year":"2009","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.repc.2016.04.006_bib0350","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","article-title":"Long\u2010term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention and research directions: a scientific statement from the American Heart Association","volume":"128","author":"Lipshultz","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2016.04.006_bib0355","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","volume":"57","author":"Fallah-Rad","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2016.04.006_bib0360","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin\u2010induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med."},{"key":"10.1016\/j.repc.2016.04.006_bib0365","unstructured":"MD Anderson Cancer Center. Cancer and the heart programs. [acedido 16 Nov 2015]. Dispon\u00edvel em: www.cancerandtheheart.org"},{"key":"10.1016\/j.repc.2016.04.006_bib0370","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer."},{"key":"10.1016\/j.repc.2016.04.006_bib0375","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1200\/JCO.2007.14.9401","article-title":"Anthracycline cardiotoxicity: from bench to bedside","volume":"26","author":"Gianni","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.repc.2016.04.006_bib0380","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","article-title":"Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia","volume":"23","author":"Lipshultz","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.repc.2016.04.006_bib0385","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.2011.40.4012","article-title":"Underestimating cardiac toxicity in cancer trials: lessons learned?","volume":"30","author":"Witteles","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.repc.2016.04.006_bib0390","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2\u2010positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2016.04.006_bib0395","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2\u2010year follow\u2010up of trastuzumab after adjuvant chemotherapy in HER2\u2010positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet."},{"key":"10.1016\/j.repc.2016.04.006_bib0400","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","article-title":"Trastuzumab\u2010related cardiotoxicity: calling into question the concept of reversibility","volume":"25","author":"Telli","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.repc.2016.04.006_bib0405","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med."},{"key":"10.1016\/j.repc.2016.04.006_bib0410","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients under\u2010 going high\u2010dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2016.04.006_bib0415","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab\u2010induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.repc.2016.04.006_bib0420","series-title":"Cardiotoxicity of Oncologic Treatments.","article-title":"Trastuzumab and Cardiotoxicity","author":"Fiuza","year":"2012"},{"key":"10.1016\/j.repc.2016.04.006_bib0425","first-page":"1787","article-title":"Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2016.04.006_bib0430","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2016.04.006_bib0435","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ahj.2009.05.031","article-title":"Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab","volume":"158","author":"Hare","year":"2009","journal-title":"Am Heart J."},{"key":"10.1016\/j.repc.2016.04.006_bib0440","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.109.211276","article-title":"Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern?","volume":"106","author":"Peng","year":"2010","journal-title":"Circ Res."},{"key":"10.1016\/j.repc.2016.04.006_bib0445","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdp018","article-title":"Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor","volume":"20","author":"Levy","year":"2009","journal-title":"Ann Oncol."},{"key":"10.1016\/j.repc.2016.04.006_bib0450","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/annonc\/mdm550","article-title":"Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation","volume":"19","author":"Mourad","year":"2008","journal-title":"Ann Oncol."},{"key":"10.1016\/j.repc.2016.04.006_bib0455","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.repc.2016.04.006_bib0460","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2016.04.006_bib0465","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1161\/HYPERTENSIONAHA.114.04116","article-title":"Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide\u2010sensitive human hypertension","volume":"64","author":"Okamoto","year":"2014","journal-title":"Hypertension."},{"key":"10.1016\/j.repc.2016.04.006_bib0470","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/HYPERTENSIONAHA.112.196774","article-title":"Management of antiangiogenic therapy\u2010induced hypertension","volume":"60","author":"Jesus-Gonzalez","year":"2012","journal-title":"Hypertension."},{"key":"10.1016\/j.repc.2016.04.006_bib0475","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cardiores.2007.06.004","article-title":"The importance of endothelin\u20101 for vascular dysfunction in cardiovascular disease","volume":"76","author":"Bohm","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.repc.2016.04.006_bib0480","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.critrevonc.2011.01.009","article-title":"Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists","volume":"80","author":"Ederhy","year":"2011","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1016\/j.repc.2016.04.006_bib0485","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens."},{"key":"10.1016\/j.repc.2016.04.006_bib0490","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fonc.2015.00039","article-title":"Radiation\u2010induced heart disease: pathologic abnormalities and putative mechanisms","volume":"5","author":"Taunk","year":"2015","journal-title":"Front Oncol."},{"key":"10.1016\/j.repc.2016.04.006_bib0495","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ijrobp.2009.09.064","article-title":"Radiation\u2010related heart disease: current knowledge and future prospects","volume":"76","author":"Darby","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.repc.2016.04.006_bib0500","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2016.04.006_bib0505","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1200\/JCO.2011.34.5900","article-title":"Distribution of coronary artery stenosis after radiation for breast cancer","volume":"30","author":"Nilsson","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.repc.2016.04.006_bib0510","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jacc.2009.11.053","article-title":"Understanding radiation\u2010induced vascular disease","volume":"5512","author":"Weintraub","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2016.04.006_bib0515","doi-asserted-by":"crossref","first-page":"317659","DOI":"10.4061\/2011\/317659","article-title":"Radiation\u2010induced heart disease: a clinical update","volume":"2011","author":"Yusuf","year":"2011","journal-title":"Cardiol Res Pract"},{"key":"10.1016\/j.repc.2016.04.006_bib0520","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","article-title":"Cardiac complications of thoracic irradiation","volume":"61","author":"Jaworski","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2016.04.006_bib0525","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/ehjci\/jet123","article-title":"Expert consensus for multi\u2010modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"14","author":"Lancellotti","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"10.1016\/j.repc.2016.04.006_bib0530","first-page":"190","article-title":"The prevention of cardiovascular disease in cancer survivors","volume":"39","author":"Daher","year":"2012","journal-title":"Tex Heart Inst J."},{"key":"10.1016\/j.repc.2016.04.006_bib0535","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr."},{"issue":"suppl 7","key":"10.1016\/j.repc.2016.04.006_bib0540","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines","volume":"23","author":"Curigliani","year":"2012","journal-title":"Ann Oncol."},{"key":"10.1016\/j.repc.2016.04.006_bib0545","article-title":"Cardio\u2010oncology","author":"Fernandez","year":"2015","journal-title":"CTO"},{"key":"10.1016\/j.repc.2016.04.006_bib0550","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1200\/JCO.2014.58.9465","article-title":"Cardiac monitoring during adjuvant trastuzumab\u2010based chemotherapy among older patients with breast cancer","volume":"33","author":"Chavez-MacGregor","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.repc.2016.04.006_bib0555","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1161\/CIRCULATIONAHA.114.010486","article-title":"Myocardial protection during cardiotoxic chemotherapy","volume":"132","author":"Witteles","year":"2015","journal-title":"Circulation."},{"key":"10.1016\/j.repc.2016.04.006_bib0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.repc.2016.04.006_bib0565","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio\u2010oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.repc.2016.04.006_bib0570","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1478-4491-11-19","article-title":"Ten principles of good interdisciplinary team work","volume":"11","author":"Nancarrow","year":"2013","journal-title":"Hum Resour Health."},{"key":"10.1016\/j.repc.2016.04.006_bib0575","first-page":"246","article-title":"Onco\u2010cardiology: the time has come","volume":"38","author":"Yeh","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.repc.2016.04.006_bib0580","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mayocp.2015.09.009","article-title":"Prevalence of preexisting cardiovascular disease in patients with different types of cancer: The Unmet Need for Onco\u2010Cardiology","volume":"9","author":"Al-Kindi","year":"2016","journal-title":"Mayo Clin Proc."},{"key":"10.1016\/j.repc.2016.04.006_bib0585","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1093\/eurheartj\/eht234","article-title":"ESC core curriculum for the general cardiologist (2013)","volume":"34","author":"Gillebert","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2016.04.006_bib0590","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jacc.2015.03.017","article-title":"ACC 2015 core cardiovascular training statement 4 (COCATS 4) (Revision of COCATS 3)","volume":"65","author":"Halperin","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.repc.2016.04.006_bib0595","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11739-011-0744-y","article-title":"Cardiovascular toxicity of anticancer\u2010targeted therapy: emerging issues in the era of cardio\u2010oncology","volume":"7","author":"Rashi","year":"2012","journal-title":"Intern Emerg Med."},{"key":"10.1016\/j.repc.2016.04.006_bib0600","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jacc.2012.05.066","article-title":"Cancer genetics and the cardiotoxicity of the therapeutics","volume":"61","author":"Lal","year":"2013","journal-title":"J Am Coll Cardiol."}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"pt","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255116301020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255116301020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:04:33Z","timestamp":1760108673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255116301020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0870255116301020"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2016.04.006","relation":{},"ISSN":["0870-2551"],"issn-type":[{"type":"print","value":"0870-2551"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Organiza\u00e7\u00e3o e implementa\u00e7\u00e3o de uma consulta de cardio\u2010oncologia","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2016.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}